Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New skin cancer drug recommended by NICE for NHS use

  • Comment

A new drug for skin cancer patients should be made available for widespread use on the NHS, health officials have said.

The drug dabrafenib (Tafinlar) can have a “rapid positive effect” on patients with a certain type of melanoma, according to the National Institute for Health and Care Excellence (NICE).

Final draft guidance from NICE suggested that the drug should be made available provided that it was sold to the NHS at a discount.

“Drugs like dabrafenib are also thought to have very rapid positive effect for patients”

Carole Longson

The drug, marketed by British pharmaceutical giant GlaxoSmithKline, targets a specific type of skin cancer that tests positive for the BRAF V600 mutation.

It works by causing cancer cells with the mutation to die, which can slow or stop the growth of the cancer.

The guidance says the drug should be made available for patients whose cancer had spread or could not be completely removed by surgery and tested positive for the mutation.

Professor Carole Longson, director for the Centre for Health Technology Evaluation at NICE, said: “For a long time, the treatments available for skin cancer which has spread have been very limited.

“However, in recent years, a number of breakthrough treatments that can potentially significantly improve the prognosis for some people with malignant melanoma have become available,” she said.

“NICE has already recommended vemurafenib and ipilimumab and we hope to add dabrafenib to the list of options available.”

She added: “The information provided by GlaxoSmithKline, who market the drug, suggested that dabrafenib works just as well as vemurafenib which also targets melanoma with the BRAF V600 mutation.

“Drugs like dabrafenib are also thought to have very rapid positive effect for patients, even in those who are very unwell or bed-ridden,” she said. “In some cases, it has enabled people to resume everyday activities.”

Welcoming the news, Professor Paul Workman, interim chief executive of The Institute of Cancer Research, said: “It’s great news that NICE has given the green light to use of dabrafenib on the NHS.

ICR

Paul Workman

“Its approval underlines the importance of a new generation of cancer drugs targeted at specific molecular features of tumours – drugs which after years of painstaking development are now making their way to patients,” he said.

“The discovery of dabrafenib was underpinned by research done here at The Institute of Cancer Research, and its approval increases the treatment options available on the NHS for patients with metastatic melanoma,” he added.

 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.